Can Abbott’s AI Innovation and Dividend Track Record Propel Its Shares?

As Abbott Laboratories prepares to release its quarterly earnings, investor focus is split between a promising new product announcement and the company’s enduring commitment to shareholder returns. The medical device giant recently showcased its latest innovation at CES 2026, while simultaneously extending a notable dividend record.

The spotlight at the tech conference fell on ‘Libre Assist,’ a new AI-powered feature for Abbott’s FreeStyle Libre continuous glucose monitoring ecosystem. Unlike traditional retrospective data, this tool aims to predict an individual’s glucose response to specific foods, offering recommendations before a meal. This proactive approach addresses a significant practical challenge for diabetes management and could strengthen Abbott’s competitive position in Read more...